pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

eureka-therapeutics PRESS RELEASE ARCHIVE

Jun 6, 2023

Eureka Therapeutics Awarded $10.6 Million CIRM Grant to Support Clinical Trial of ARTEMIS T-Cell Therapy in Pediatric Liver Cancer

Mar 14, 2023

Eureka Therapeutics Licenses Promising Antibody Targeting Mesothelin from the National Cancer Institute

Oct 18, 2022

Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS T Cell Therapy for Neuroblastoma

Oct 17, 2022

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatoblastoma with ET140203 ARTEMIS T cells

Sep 28, 2022

Eureka Therapeutics Announces New England Journal of Medicine Publication of Clinical Study Demonstrating GPRC5D as an Active Target for the Treatment of Multiple Myeloma

Aug 3, 2022

Eureka Therapeutics Announces Publication of Crystal Structure of TCR Mimic Redirected T Cells Targeting Alpha-Fetoprotein (AFP) for Liver Cancer

Jun 6, 2022

Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80

May 31, 2022

Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS T Cells (ECT204) for Advanced Liver Cancer

Apr 25, 2022

Eureka Therapeutics to Present at the 18th Annual PEGS Boston Conference and Expo

Feb 8, 2022

Eureka Therapeutics Receives Orphan Drug Designations for Treatment of Hepatocellular Carcinoma (HCC) With ARTEMIS T Cells

Nov 17, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-2 Clinical Trial of ET140203 ARTEMIS T Cells to Treat Pediatric Liver Cancer

Nov 1, 2021

Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours

Jul 21, 2021

Eureka Therapeutics Announces Initiation of Phase I/II ARYA-3 Clinical Trial of GPC3 Targeting ARTEMIS T Cell Therapy in Liver Cancer

Jul 6, 2021

Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma

Dec 14, 2020

Eureka Therapeutics Announces Successful Preclinical Results of InvisiMask™ Human Antibody Nasal Spray Against SARS-CoV-2 Infection

Nov 9, 2020

Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. to its Scientific Advisory Board

Oct 13, 2020

Eureka Therapeutics to Present at Two Upcoming Virtual Conferences

Oct 5, 2020

Eureka Therapeutics Announces Initiation of ARYA-1 Clinical Trial to Evaluate ET140203 ARTEMIS T Cell Therapy in Hepatocellular Carcinoma

Jul 20, 2020

JW Therapeutics Acquires Syracuse Biopharma and License to Eureka Therapeutics’ Solid Tumor Technology in China

Jun 25, 2020

Eureka Therapeutics to Present at Oppenheimer's Private Life Sciences Company Call Series

Mar 17, 2020

Eureka Therapeutics Completes $45 Million Series E Financing and Enters Into Strategic Collaboration With Lyell Immunopharma

Mar 3, 2020

Eureka Therapeutics Announces Upcoming Conference Presentations

Feb 20, 2020

Eureka Therapeutics to Present at 6th Annual Immuno-Oncology 360° Conference

Feb 18, 2020

Eureka Therapeutics to Present at the CAR-TCR Summit Europe

Dec 3, 2019

Eureka Therapeutics to Present New Clinical Data of anti-CD19 ARTEMIS™ 3.0 T-cell Therapy at 2019 ASH Annual Meeting

Oct 31, 2019

Eureka Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting

Aug 5, 2019

Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of ET140202 ARTEMIS™ T-Cell Therapy in Liver Cancer

Apr 15, 2019

Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating Selective Depletion of Tregs Using Foxp3 Targeting TCR-mimic Antibody

Mar 27, 2019

Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating GPRC5D as a Promising Target for Antibody-Based Therapies in Multiple Myeloma

Jan 30, 2019

Eureka Therapeutics Announces US FDA Clearance of IND Application for Phase 1/2 Trial of ET140202 Artemis T-Cell Therapy, for the Treatment of Liver Cancer

Nov 30, 2018

Eureka Therapeutics Announces Data Presentations Validating Its Proprietary E-ALPHA Discovery Platform at the 2018 ASH Annual Meeting

Nov 21, 2018

Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity

Sep 5, 2018

Eureka Therapeutics Achieves Regression of Metastatic Liver Cancer Using ET140202 T-cell Therapy

Aug 30, 2018

Eureka Therapeutics to Present Proof-of-Concept Preliminary Data from Ongoing China Clinical Study of ET140202 at CAR-TCR 2018 Summit

Aug 16, 2018

Eureka Therapeutics Announces Publication of Armored T-Cell Proof-of-Concept Study in Nature Biotechnology

Jul 17, 2018

Eureka Therapeutics Announces that Boehringer Ingelheim is Exercising an Option to License Novel TCR Mimic (TCRm) Antibodies

Jun 4, 2018

Eureka Therapeutics Announces Positive Preliminary Results of ET190L1-ARTEMISTM T-cell China Proof-of-Concept Human Clinical Study in Relapsed and Refractory (r/r) B-cell Lymphoma at ASCO Annual Meeting

Jan 22, 2018

Eureka Therapeutics Closes $60 Million in Series D Financing to Advance Proprietary ARTEMIS™ T Cell Receptor Platform for Safer T Cell Therapies

Sep 13, 2017

Eureka Therapeutics Announces Presentations at Upcoming Industry Conferences

Jun 7, 2017

Eureka Therapeutics and City of Hope Announce Agreement to Conduct Phase 1 Clinical Trial of Investigational ET1402L1 CAR-T Therapy in Liver Cancer

Apr 20, 2017

Eureka Therapeutics Expands Scientific Advisory Board with Appointment of Industry Leaders Dr. Hideho Okada and Dr. Nai-Kong Cheung

Aug 4, 2016

Juno Therapeutics Announces Multiple Myeloma Partnership with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for Developing CAR T Cell Immunotherapy Against Multiple Novel Targets

Jan 7, 2016

Eureka Therapeutics Announces Exclusive License Agreement between Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Use of a Novel, Fully-Human MUC16 Binder in CAR T Cell Immunotherapy

Google Analytics Alternative